» Articles » PMID: 30848565

Enabling Large-Scale Ex Vivo Production of Megakaryocytes from CD34 Cells Using Gas-Permeable Surfaces

Overview
Date 2019 Mar 9
PMID 30848565
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Patients suffering from acute or sustained thrombocytopenia require platelet transfusions, which are entirely donor-based and limited by challenges related to storage and fluctuating supply. Developing cell-culture technologies will enable ex vivo and donor-independent platelet production. However, critical advancements are needed to improve scalability and increase megakaryocyte (Mk) culture productivity. To address these needs, we evaluated Mk production from mobilized peripheral blood CD34 cells cultured on a commercially available gas-permeable silicone rubber membrane, which provides efficient gas exchange, and investigated the use of fed-batch media dilution schemes. Starting with a cell-surface density of 40 × 10 CD34 cells per cm (G40D), culturing cells on the membrane for the first 5 days and employing media dilutions yielded 39 ± 19 CD41 CD42b Mks per input CD34 cell by day 11-a 2.2-fold increase compared with using standard culture surfaces and full media exchanges. By day 7, G40D conditions generated 1.5-fold more CD34 cells and nearly doubled the numbers of Mk progenitors. The increased number of Mk progenitors coupled with media dilutions, potentially due to the retention of interleukin (IL)-3, increased Mk production in G40D. Compared with controls, G40D had higher viability, yielded threefold more Mks per milliliter of media used and exhibited lower mean ploidy, but had higher numbers of high-ploidy Mks. Finally, G40D-Mks produced proplatelets and platelet-like-particles that activate and aggregate upon stimulation. These results highlight distinct improvements in Mk cell-culture and demonstrate how new technologies and techniques are needed to enable clinically relevant production of Mks for platelet generation and cell-based therapies.

Citing Articles

Inside-to-outside and back to the future of megakaryopoiesis.

Di Buduo C, Miguel C, Balduini A Res Pract Thromb Haemost. 2023; 7(4):100197.

PMID: 37416054 PMC: 10320384. DOI: 10.1016/j.rpth.2023.100197.


Engineered cord blood megakaryocytes evade killing by allogeneic T-cells for refractory thrombocytopenia.

Kumar B, Afshar-Kharghan V, Mendt M, Sackstein R, Tanner M, Popat U Front Immunol. 2022; 13:1018047.

PMID: 36203567 PMC: 9530569. DOI: 10.3389/fimmu.2022.1018047.


Beyond the thrombus: Platelet-inspired nanomedicine approaches in inflammation, immune response, and cancer.

Desai C, Koupenova M, Machlus K, Sen Gupta A J Thromb Haemost. 2022; 20(7):1523-1534.

PMID: 35441793 PMC: 9321119. DOI: 10.1111/jth.15733.


Differentiated Cells Derived from Hematopoietic Stem Cells and Their Applications in Translational Medicine.

Fernandes S, Limaye L, Kale V Adv Exp Med Biol. 2021; 1347:29-43.

PMID: 34114129 DOI: 10.1007/5584_2021_644.


The Blood Circulating Rare Cell Population. What is it and What is it Good For?.

Schreier S, Triampo W Cells. 2020; 9(4).

PMID: 32218149 PMC: 7226460. DOI: 10.3390/cells9040790.

References
1.
Lambert M, Sullivan S, Fuentes R, French D, Poncz M . Challenges and promises for the development of donor-independent platelet transfusions. Blood. 2013; 121(17):3319-24. PMC: 3976218. DOI: 10.1182/blood-2012-09-455428. View

2.
Bird G, Polsky A, Estes P, Hanlon T, Hamilton H, Morton J . Expansion of human and murine hematopoietic stem and progenitor cells ex vivo without genetic modification using MYC and Bcl-2 fusion proteins. PLoS One. 2014; 9(8):e105525. PMC: 4149411. DOI: 10.1371/journal.pone.0105525. View

3.
Eicke D, Baigger A, Schulze K, Latham S, Halloin C, Zweigerdt R . Large-scale production of megakaryocytes in microcarrier-supported stirred suspension bioreactors. Sci Rep. 2018; 8(1):10146. PMC: 6033877. DOI: 10.1038/s41598-018-28459-x. View

4.
Sugimoto N, Eto K . Platelet production from induced pluripotent stem cells. J Thromb Haemost. 2017; 15(9):1717-1727. DOI: 10.1111/jth.13736. View

5.
Borst S, Sim X, Poncz M, French D, Gadue P . Induced Pluripotent Stem Cell-Derived Megakaryocytes and Platelets for Disease Modeling and Future Clinical Applications. Arterioscler Thromb Vasc Biol. 2017; 37(11):2007-2013. PMC: 5675007. DOI: 10.1161/ATVBAHA.117.309197. View